Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD25I6)

Drug Name
MERCK-544 Drug Info
Synonyms
MERCK-544; 327093-42-5; CHEMBL256777; 3-ADAMANTAN-1-YL-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[4.3-A]AZEPINE; Compound 544; 3-(Adamantan-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine; AC1MTUPG; Merck 544; Oprea1_175789; SCHEMBL5095978; DTXSID40394475; ZINC5494877; BDBM50239401; AKOS015969399; 3-(1-adamantyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine; MCULE-4943397141; SR-01000029295; SR-01000029295-1; Z55729757; 3-(adamantan-1-yl)-5H,6H,7H,8H,9H-[1,2,4]triazolo[4,3-a]azepine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3630776
CAS Number
CAS 327093-42-5
TTD Drug ID
DMD25I6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GLYCYRRHIZIN DM8M2N3 Influenza virus infection 1E30-1E32 Phase 3 [2]
BVT.2733 DM6RUKX Lupus 4A40 Phase 3 [3]
INCB13739 DMLQ3PO Type-2 diabetes 5A11 Phase 2a [4]
URSOLIC ACID DM4SOAW Metabolic syndrome x 5C50-5D2Z Phase 2 [5]
JTT-654 DM50M2R Type-2 diabetes 5A11 Phase 2 [6]
RG-4929 DMT4QRD Metabolic disorder 5C50-5D2Z Phase 2 [6]
BMS-770767 DMTVGY7 Hypercholesterolaemia 5C80.0 Phase 2 [6]
UE-2343 DMIERPK Alzheimer disease 8A20 Phase 2 [7]
AZD-4017 DML9M5S Ocular hypertension 9C61.01 Phase 2 [6]
Xanamem DM580GT Alzheimer disease 8A20 Phase 1/2 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) TTN7BL9 DHI1_HUMAN Inhibitor [1]

References

1 Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1551-4.
2 Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32.
3 Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62.
4 Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.
5 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
6 New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem?). Br J Pharmacol. 2017 Mar;174(5):396-408.